Alpback Workshop

MENU menu

9th Alpbach Workshop on
Affinity Proteomics
March 11-13 2019



Mathias Uhlen’s research is focused on protein science, antibody engineering and precision medicine and ranges from basic research in human and microbial biology to more applied research, including clinical applications in cancer, infectious diseases, cardiovascular diseases, autoimmune diseases and neurobiology. It has resulted in more than 550 publications with a current h-index of 98. His group was the first to describe a number of innovations including: engineered protein A and protein G for purification of antibodies, affinity tags for purification of recombinant fusion proteins, solid phase techniques for DNA handling using the biotin-streptavidin system, Pyrosequencing leading to the first next generation DNA sequencing instrument (454/Roche), and Affibodies, protein binders aimed at therapeutic applications. Since 2003, he has led an international effort to systematically map the human proteome with antibodies and to create an open source knowledge-based resource called the Human Protein Atlas (

Mathias Uhlen


Ulf Landegren MD PhD is Professor of Molecular Medicine in Uppsala University, where his group develops molecular tools for precision medicine at the levels of nucleic acids and proteins. He is a member of EMBO, the Royal Swedish Academy of Sciences and the Scientific Advisory Committee for European Academies, as well as several industrial scientific advisory boards. He has authored 200 peer-reviewed publications, and is the inventor of 40 patents. Technologies his group has developed have been licensed to 11 international biotech and diagnostic companies, and to six companies spun out from his lab.

Ulf Landegren


Professor Kathryn Lilley is Director of the University of Cambridge Centre for Proteomics. This state-of-the-art Centre, which she established in 2000, collaborates with a large number of groups in the UK and worldwide. Her laboratory is at the forefront of technology development which enables measurement of the dynamics of the proteome in high throughput manner and in space and time during critical cellular processes such as signalling and differentiation. Her group has also contributed many open-source informatics tools necessary to efficiently mine and visualise the extremely complex data which is produced by spatiotemporal proteomics studies. She has recently has been awarded a Wellcome Trust Investigator Award to investigate the implication of where transcripts are translated upon the spatial proteome and how this process is controlled. 


Dr. H. Tom Soh is a Professor of Electrical Engineering and Radiology at Stanford University. He received his B.S. with a double major in Mechanical Engineering and Materials Science with Distinction from Cornell University, and his Ph.D. in Electrical Engineering from Stanford.  Between 1999 and 2003, he served as a technical manager of MEMS device research group at Bell Laboratories and Agere Systems.  Between 2003 and 2015, he was the Ruth Garland Professor at UC-Santa Barbara (UCSB) in the department of Mechanical Engineering and Materials.  His laboratory develops synthetic reagents and biosensors to measure biomolecules in complex environments.  He is a recipient of numerous awards including MIT Technology Review’s "TR 100" Award (2002), ONR Young Investigator Award (2004), Beckman Young Investigator Award (2005), ALA Innovator Award (2009), NIH Director’s TR01 Award (2009), John Simon Guggenheim Fellowship (2010), NIH Edward Nagy Award (2011), and Alexander von Humboldt Fellowship (2012).


Jonathan, co-Founder and currently Deputy Chairman of Abcam plc, is an entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. 

Jonathan gained his doctorate in Molecular Genetics at Leicester University. From 1992-95, he was a post-doctoral researcher at Bath, following which he worked at the University of Cambridge researching the molecular basis of breast cancer. He identified the market opportunity for supplying high-quality antibodies to support protein interaction studies, and in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is a non-executive director of Horizon Discovery, Frontier Developments, Syndicate Room and GeoSpock. He is also Chairman of Axol Bioscience, Cambridge Allergy Therapy, PhoreMost, Repositive and DefiniGEN, and sits on the advisory boards of Desktop Genetics and Healx. In 2015 Jonathan, with Professor Tony Kouzarides, co-founded the Milner Therapeutics Institute at the University of Cambridge. Also in 2015 he co-founded, with Professor Laurence Hurst, the Milner Institute for Evolution at the University of Bath.


Stefan Dübel co-pioneered in-vitro antibody selection technologies, resulting in several key inventions including antibody phage display (USPat. 5849500) and human antibody libraries with randomized CDRs (USPat. 5840479). Other technologies developed in his lab, e.g. Hyperphage technology, are also broadly used by labs all over the world. His lab further contributed to multiple topics related to antibody engineering, fusion proteins for cancer therapy, and high throughput human antibody generation. Recently, his lab introduced protein knockdown mice based on intrabody technology. He has published >200 scientific papers and is Editor of the four volume reference "Handbook of Therapeutic Antibodies“. He is Full Professor of Biotechnology and Director of the respective department at the Technische Universität Braunschweig, Germany, and co-founder of the human antibody company YUMAB.

Stefan Dubel


Jörg Hoheisel heads the Division of Functional Genome Analysis at the Deutsches Krebsforschungszentrum (DKFZ; German Cancer Research Center) in Heidelberg, Germany. His research objective is the development and immediate application of technologies for an assessment and description of the realisation and regulation of cellular function from genetic information. He currently has a particular focus on the analysis of protein variations and interactions by means of affinity proteomics. Another line of work is Synthetic Biology for the in vitro production of functional biomolecules and the establishment of artificial molecular systems. Earlier achievements were his involvement in the sequencing of the yeast genome as a coordinator and developments in the area of microarray technology. Jörg has also co-founded five companies; another four were formed independently by former group members.

Jog Hoheisel


Andreas Plückthun is Professor of Biochemistry at the University of Zürich. His research is centered on protein engineering. His contributions have included many aspects of structure-based antibody engineering, expression technology, design of synthetic antibody libraries, the development of ribosome display as an in vitro protein evolution technology, development of new scaffolds (the DARPin technology), and the directed evolution of G-protein coupled receptors towards high stability. His lab is combining computer-aided protein design, directed evolution, biophysics and cell biology. He is a member of the German Academy of Science (Leopoldina) and EMBO. His work has been published in over 400 papers, which have been cited over 33,000 times (h-index 106). He has receive numerous prizes including the 2016 Christian Anfinsen Award for "pioneering contributions to protein engineering". He co-founded MorphoSys AG (1992), Molecular Partners AG in Zurich (2004) and G7 Therapeutics in Zurich (2014). 


Hanno Langen is a biochemist by training. After a postdoctoral fellowship at the Rockefeller University in New York he joined Roche in Basel. His research is focused on the pharmaceutical and diagnostic application of proteomics in the field of Biomarker discovery and validation by using high throughput mass spectrometry and ELISA technologies. He has over a hundred Patent applications and scientific papers. Currently he is Distinguished Scientist in Translation Research Sciences.  He is teaching in addition to his position in the pharmaceutical industry as Professor at the University of Basel and Bern. H. Langen is a senior Editor of the Proteomics Journal and founding member of the Human Proteome Organization.


Dr. Heng Zhu is a Full Professor at Department of Pharmacology and Molecular Sciences at Johns Hopkins University School of medicine.  He did postdoctoral research in Dr. Michael Snyder's group at Yale University when he and his colleagues invented the proteome chip technology. In 2004, he joined the faculty of the JHUM. During the years, his group has focused on the development and application of proteome microarrays to address basic and clinical questions. His group has constructed the world-largest proteome microarray, comprising ~20,000 individually purified human proteins in full-length. Using this powerful tool, his group has developed new approaches to construct signaling networks and pathways via identification of enzyme-substrate relationships and to profile DNA- and RNA-protein interactions. Dr. Zhu and colleagues also applied the human proteome microarrays to discovery novel biomarkers in autoimmune diseases and cancer.


Susanne Gräslund did her doctoral training in Biotechnology at the Royal Institute of Technology in Stockholm, Sweden, developing the concepts for what later became the Human Protein Atlas Project. After her dissertation in 2002 she worked for three years at Biovitrum AB in the Target Expression & Purification section. In March 2005, Susanne joined the newly started Structural Genomics Consortium group in Stockholm, heading the Biotechnology team responsible for the generic protein production pipeline. She was then recruited to the SGC Toronto site as Principal Investigator for the Biotechnology team in September 2011 and to manage the SGC efforts to make recombinant antibodies to SGC target proteins. In 2015, SGC established a new lab at Karolinska Institutet in Stockholm, funded by Innovative Medicines Initiative where Dr. Gräslund is having a leading role.


Michael Weiner, Ph.D. has successfully delivered several well-known products to the research marketplace, including QuikChange Mutagenesis (Stratagene Cloning Systems, over 100,000 citations in the literature), Luminex bead-based SNP genotyping, Next Generation DNA sequencing (454 Life Sciences, >6,000 citations), and microfluidic-based digital PCR (RainDance Technologies).  He is currently the VP of Molecular Sciences at Abcam where his primary responsibilities are to develop and oversee advanced methods for the discovery and production of recombinant antibodies.  His recent research has been focused on a means to identify de novo and produce high affinity IgG molecules within 2 weeks upon receipt of an antigen.

Michael Weiner


Fridtjof Lund-Johansen leads a proteomics research group at the Oslo University Hospital in Norway. The goal of his research is to develop a unified platform for antibody-and mass spectrometry (MS)-based proteomics. His technology is called Microsphere Affinity Proteomics (MAP) and involves labelling and extensive fractionation of sample proteins followed by parallel readout with MS- and microsphere-based antibody arrays.  With MAP, the targets of thousands of antibodies are resolved as discrete reactivity peaks across the fractions, and the MS results are used to identify peaks that correspond to specific binding. By allowing parallel use of thousands of antibodies, MAP brings a true proteomics perspective into the field of antibody-based detection.


Dr. Janice Reichert is an internationally-recognized expert in the development of antibody therapeutics. She is Executive Director of The Antibody Society, a non-profit association representing individuals and organizations that engage in antibody research or development. Dr. Reichert is also Founder and Editor-in-Chief of mAbs, a peer-reviewed, PubMed-indexed biomedical journal that focuses on topics relevant to antibody R&D, and Founder and Managing Director of Reichert Biotechnology Consulting LLC, a pharmaceutical business intelligence research firm. Dr. Reichert writes frequently on development trends for antibody therapeutics, and she has presented her research results as an invited speaker at conferences held worldwide.



Carl Borrebaeck received the first chair as professor of Immunotechnology in Scandinavia 1989. His main research interests are cancer proteomics, for early detection and prognosis, and antibody engineering, for the generation of human therapeutic antibodies and founded CREATE Health Translational Cancer Center 2006. He is a permanent member of the Royal Swedish Academy of Engineering Sciences. He received the AKZO Nobel Science Award 2009, for his contributions to cancer proteomics and antibody-based therapy, the Research!Sweden Award 2012 for his medical research of value for patients and health organizations, and the Royal Academy of Engineering Sciences Gold Medal 2012 for outstanding contributions to biomedical science. His research has resulted in several spin-out companies, such as BioInvent International AB, Alligator Bioscience AB, Immunovia AB, SenzaGen AB and Atlas Therapeutic.

Carl Borrebaeck


Andrew Bradbury is group leader in the Biosciences division at Los Alamos National Laboratory, New Mexico. He has worked in the field of phage display and antibody engineering for almost 30 years.  He was a founder member and the first president (2007-2010) of The Antibody Society, a professional society for all aspects of antibodies. He has published over 130 peer-reviewed articles, including reviews and perspectives on phage display and antibody engineering. He recently published a commentary in Nature calling for changes in the way research antibodies are supplied, arguing that they should be sequenced and expressed recombinantly in order to improve reproducibility. His present research interests lie in improving in vitro display technologies in order to make in vitro antibody selection the preferred method to generate highly specific, high affinity antibodies. Within this context he has developed an antibody selection pipeline that combines phage and yeast display in methods that exploit the advantages of each. 

Andrew Bradbury


Dr Alejandra Solache joined Abcam in 2013 as Head of Product Development and Manufacturing globally.  She is responsible for managing the output of the Abcam Cambridge, Hangzhou and Bristol laboratories, specifically the New Product Development reagents pipelines and R&D.  She also plays a key role in developing Abcam’s innovation strategy. Prior to joining Abcam she held various positions at EMD-Millipore, latterly as R&D Director, leading the Antibody and Assay Development teams.  She gained expertise in Immunology, cell signalling and Cell Biology through postdoctoral fellowships at UCSF and the Trudeau Institute. She holds a PhD in Immunology and an MSc in Biochemistry.


Peter Nilsson is a Professor in Proteomics at SciLifeLab, KTH - Royal Institute of Technology, in Stockholm, Sweden. He received his PhD degree in Biotechnology from KTH in 1998. Since 2002, he has been the head of the Protein Microarray group within the Human Protein Atlas and the director of the Affinity Proteomics national platform at SciLifeLab since 2013. He is also the Vice Dean of KTH School of Biotechnology.  Peter has been a member of the steering group of HUPO Human Brain Proteome Project (HBPP) since 2015. His research focus is based on the development and utilisation of various antibody, protein, peptide and serum microarray technologies for protein and autoantibody profiling in body fluids and biomarker discovery applications, mainly within neuroscience and inflammation. For publications see


Professor Trimmer's research program focuses on the expression, localization and function of neuronal ion channel complexes at the proteomic level, and on generation, validation and use of antibodies in diverse neuroscience research applications. He also directs the UC Davis/NIH NeuroMab Facility that generates high qualicty, low cost monoclonal antibodies for neuroscience research. Validation efforts include diverse assays on brain samples, and transparent reporting of the results, enhancing the utility of NeuroMabs across many areas of neuroscience research. These efforts have resulted in distribution of over 50,000 vials of low cost antibodies, and over 2,000 research publications citing the facility.


John McCafferty was one of the founders of Cambridge Antibody Technology (CAT, now Medimmune) in 1990 and published the first paper/patent describing antibody phage display. After 12 years at CAT, John set up groups at the Sanger Institute and then The University of Cambridge developing and utilising methods for protein generation and recombinant antibody isolation for research and therapeutic applications. In 2012 John formed IONTAS, a small innovative biotechnology company using phage display to develop novel antibody therapeutics. In addition IONTAS are developing novel technologies allowing discovery of IgG formatted antibodies directly from very large mammalian display libraries.


Martin Lundberg is a Senior Scientist at Olink Proteomics. The goal of his research is to further develop products and molecular tools used for protein detection. He is one of the co-inventors of the Proximity Extension Assay (PEA) and has since 2009 worked with the development of highly multiplexed biomarker panels. Another area of focus is to adapt the PEA technology to a diagnostic setting, where the ultimate goal is to develop multiplexed protein panels for diagnostics and patient stratification.


John Rogers is a Senior R&D Manager at Thermo Scientific where he manages the development of new reagents and kits for protein mass spectrometry research.  John has an undergraduate degree in Biochemistry and Computer Science and a Ph.D in Pharmacology from the University of Washington.  John managed a bioinformatics group at Parke-Davis/Pfizer and a proteomics group at Abbott before joining Thermo Fisher Scientific in 2007.  Since joining Thermo, John has led the development of new MS standards and calibrants, protein sample preparation reagents, reagents for quantitative proteomic analysis, and new workflows for antibody verification using immunoprecipitation with mass spectrometry.


Jochen M. Schwenk is Associate Professor for Translational Proteomics at KTH - Royal Institute of Technology in Stockholm, Sweden. He is the Director of the Biobank Profiling facility at the Science for Life Laboratory and a Principal Investigator within the Human Protein Atlas and the KTH Center for Applied Precision Medicine (KCAP). Jochen is the current chair of HUPO’s Plasma Proteome Project (HPPP) and represents the Antibody Resource Pillar in the executive committee of Human Proteome Project. Jochen’s research focuses on affinity proteomics methods for multiplexed bead-based plasma analysis in large sample sets from population and different disease areas. With the aim to translate discoveries into applications, his team is working on novel affinity-based assays, methods for antibody validation, mass spectrometry, experimental study designs, processing of data and statistical analyses.


Karl-Friedrich Becker heads the Laboratory for Experimental Pathology at the Technical University of Munich. His lab uses unique methods for protein analysis of tissues, e.g. extraction of intact proteins from formalin-fixed and paraffin-embedded (FFPE) tissues and Reverse Phase Protein Arrays (RPPA), for which he was awarded with the Novartis Research Prize for Pathology.
Since 2012 Dr. Becker is member and project leader of the European Committee for Standardization (CEN) TC140 „In vitro diagnostic medical devices“, WG3 „Quality Management in the Medical Laboratory“ and since 2014 member and project leader of the International Organization for Standardization (ISO) TC212 “Clinical laboratory testing and in vitro diagnostic test systems”.
Since June 2016 Dr. Becker is Scientific Director of the Tissue Biobank of the Medical School of the Technical University of Munich. 


David Juncker is Professor in the Biomedical Engineering Department and the McGill University and Genome Quebec Innovation Centre at McGill University David's interests are in the areas of Micro and Nanobioengineering, and in developing novel technologies for bioanalysis and tissue engineering. He has notably developed novel antibody microarrays that are resistant to cross-reactivity, snap-chip technology for immunoassays and tissue staining, microfluidic circuits based on capillary phenomena for point-of-care diagnosis, 3D printed capillaric circuits, thread- and textile-based approaches to microfluidics and tissue engineering, the microfluidic probe, and filter technologies for circulating tumor cell isolation. Most recently, his lab is developing novel bead-based barcodes, high throughput aptamer screening methods, and nanotechnology-based exosome analysis. Two companies spun-off from his group. 


Mike Taussig, the main organiser of this workshop, is founder and CEO of Cambridge Protein Arrays Ltd. and formerly head of the Protein Technology Group at the Babraham Institute, Cambridge. He codeveloped ribosome display technology for selection of antibodies, and in situ protein arraying, and has collaborated on the production of human antibodies from transgenic mice. He has managed several large EU and ESF networking and research projects, including three EU consortia aiming to establish European resources of affinity binding reagents for analysis of the human proteome, namely ProteomeBinders (2006-2010), AffinityProteome (2009-2012) and AFFINOMICS (2010-2015). He is a board member of the European Federation of Biotechnology and Editor in Chief of the EFB journal New Biotechnology (Elsevier).  Mike is a Fellow of Selwyn College, Cambridge.